Still, CBY1 expression is reduced in hematopoietic progenitors of CML patients at clinical diagnosis compared to healthy donors and further lowered in the LSC (CD34+) compartment, where β-catenin provides a key signal for proliferation and survival [8]. Here, CBY1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.